“Chronic Spontaneous Urticaria Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Spontaneous Urticaria Market.

Chronic Spontaneous Urticaria Overview

Chronic Spontaneous Urticaria (CSU) is defined as hives present for at least or greater than 6 weeks and most days of the week. CSU results from the pathogenic activation of mast cells and basophils, which gives rise to the release of proinflammatory mediators that support the generation of urticaria.

The primary principle of Chronic Spontaneous Urticaria treatment is to eliminate symptoms, including pruritus, wheals and angioedema.

The Chronic Spontaneous Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Chronic Spontaneous Urticaria Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Spontaneous Urticaria treatment therapies with a considerable amount of success over the years. Chronic Spontaneous Urticaria Key players such as – Third Harmonic Bio, Celldex Therapeutics, United BioPharma, Amgen, Celltrion, Regeneron, Novartis, and others, are developing therapies for the Chronic Spontaneous Urticaria treatment 

• Chronic Spontaneous Urticaria Emerging therapies such as – THB001, CDX-0159, UB-221, Tezepelumab, CT-P39, Dupilumab, Ligelizumab, and others are expected to have a significant impact on the Chronic Spontaneous Urticaria market in the coming years.   
• In October 2018, Novartis initiated a Phase III multi-center, randomized, double-blind, active, and placebo-controlled study to investigate the efficacy and safety of Ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines
• In April 2020, Novartis initiated a Phase III, multicenter, double-blinded, and open-label extension study to evaluate the efficacy and safety of Ligelizumab as retreatment, self-administered therapy, and monotherapy in Chronic Spontaneous Urticaria patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301. The purpose of this extension study is to establish the efficacy and safety of ligelizumab 

Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment

The  Chronic Spontaneous Urticaria Pipeline report proffers an integral view of the Chronic Spontaneous Urticaria emerging novel therapies segmented by Stage, Product Type,  Molecule Type,  Mechanism of Action, and Route of Administration. 

DelveInsight’s Chronic Spontaneous Urticaria Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Chronic Spontaneous Urticaria Drugs Under Different Phases of Clinical Development Include:

• THB001: Third Harmonic Bio
• CDX-0159: Celldex Therapeutics
• UB-221: United BioPharma
• Tezepelumab: Amgen
• CT-P39: Celltrion
• Dupilumab: Regeneron
• Ligelizumab: Novartis 

Chronic Spontaneous Urticaria Pipeline Analysis

The Chronic Spontaneous Urticaria pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Chronic Spontaneous Urticaria treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Spontaneous Urticaria Treatment.
• Chronic Spontaneous Urticaria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Spontaneous Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Spontaneous Urticaria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. 

Further Chronic Spontaneous Urticaria product details are provided in the report. Download the Chronic Spontaneous Urticaria pipeline report to learn more about the emerging Chronic Spontaneous Urticaria therapies 

Chronic Spontaneous Urticaria Pipeline Market Drivers

• Increasing prevalence of urticaria due to changing environment and rise in the number of skin infection
• Development of Novel Chronic Spontaneous Urticaria Treatments

Chronic Spontaneous Urticaria Pipeline Market Barriers

• Difficulty in identifying the condition
• Lack of awareness about the treatment

Get a Free Sample PDF Report to know more about Chronic Spontaneous Urticaria Pipeline Assessment

Scope of Chronic Spontaneous Urticaria Pipeline Drug Insight    

• Coverage:  Global
• Key Chronic Spontaneous Urticaria Companies:  Third Harmonic Bio, Celldex Therapeutics, United BioPharma, Amgen, Celltrion, Regeneron, Novartis, and others
• Key Chronic Spontaneous Urticaria Therapies:  THB001, CDX-0159, UB-221, Tezepelumab, CT-P39, Dupilumab, Ligelizumab, and others
• Chronic Spontaneous Urticaria Therapeutic Assessment:  Chronic Spontaneous Urticaria current marketed and Chronic Spontaneous Urticaria emerging therapies
• Chronic Spontaneous Urticaria Market Dynamics:  Chronic Spontaneous Urticaria market drivers and Chronic Spontaneous Urticaria market barriers 

Table of Contents

Download Sample PDF Report to know more about Chronic Spontaneous Urticaria drugs and therapies

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/